Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention

EuroIntervention

Volumn 9, Issue 5, 2013, Pages 546-555

  Yu, Xi Yong ^a   Chen, Ji Yan ^a   Zheng, Zhi Wei ^a   Wu, Hong ^b   Li, Li Wen ^a   Zhang, Zhi Wei ^a   Chen, Zhi Hong ^a   Lin, Qiu Xiong ^a   Han, Ya Ling ^c   Zhong, Shi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Shenyang Northern Hospital   (China)

Author keywords

Adverse cardiovascular events; Bleeding; Dual antiplatelet therapy; MiR 126; Percutaneous coronary intervention; Plasma miRNA

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CLOPIDOGREL; MICRORNA; MICRORNA 126; MICRORNA 16; MICRORNA 21; MICRORNA 223; MICRORNA 26B; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; MIRN126 MICRORNA, HUMAN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BLOOD LEVEL; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHINESE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; HEART DEATH; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STENT THROMBOSIS; BLOOD; HEART; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR;

AGED; CORONARY ARTERY DISEASE; FEMALE; HEART; HEMORRHAGE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84885335934     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9I5A90     Document Type: Article

References (22)

1. Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol. 2010;55:1553-65.
2. Qin S, Zhang C. MicroRNAs in vascular disease. J Cardiovasc Pharmacol. 2011;57:8-12.
3. Chamorro-Jorganes A, Araldi E, Penalva LO, Sandhu D, Fernandez-Hernando C, Suarez Y. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol. 2011;31:2595-606.
4. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res. 2010;3:251-5.
5. Gatsiou A, Boeckel JN, Randriamboavonjy V, Stellos K. MicroRNAs in platelet biogenesis and function: implications in vascular homeostasis and inflammation. Curr Vasc Pharmacol. 2012;10:524-31.
6. Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King AS, Kirkby NS, Crosby-Nwaobi R, Prokopi M, Drozdov I, Langley S, Sivaprasad S, Markus HS, Mitchell JA, Warner T, Kiechl S, Mayr M. Circulating MicroRNAs as novel biomarkers for platelet activation. Circ Res. 2013;112:595-600.
7. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15:261-71.
8. Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, Hirschhauser C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17:110-6.
9. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. 2009;16:961-6.
10. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110:483-95.
11. Tijsen AJ, Pinto YM, Creemers EE. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2012;303:H1085-95.
12. de Boer HC, van Solingen C, Prins J, Duijs JM, Huisman MV, Rabelink TJ, van Zonneveld AJ. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J. 2013 Feb 4. [Epub ahead of print].
13. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-69.
14. Braunwald E. Unstable angina. A classification. Circulation. 1989;80:410-4.
15. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials-proposal of a new classification. Am J Cardiol. 2007;99:288-90.
16. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, Ziemann M, Helbing T, El-Osta A, Jowett JB, Peter K. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. 2012;93:633-44.
17. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15:272-84.
18. Liu B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 2009;66:169-75.
19. Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu T, Bai Y, Shen Y, Yuan W, Jing Q, Qin Y. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem. 2011;351:157-64.
20. Ancrenaz V, Desmeules J, James R, Fontana P, Reny JL, Dayer P, Daali Y. The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. Br J Pharmacol. 2012;166:2362-70.
21. Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv. 2011;4:422-8.
22. Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schomig A, Kastrati A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J. 2011;32:1605-13.